Prospective studies of anti-PF4/heparin antibody formation in MPN should follow and will lead to more general recommendations for diagnostic and clinical management of PV and ET patients with anti-PF4/heparin antibodies. The gene discussed is PF4; the disease is myeloproliferative neoplasm.